Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-25 (Canceled)

Claim 26 (Currently Amended): A method for measurement of content of a residue of a drug compound introduced to a drug delivery system compound in which a polymer carrier comprising a polysaccharide derivative having carboxyl groups and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate.

Claim 27 (Currently Amended): A method for measurement of content of a residue of a drug compound introduced to a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate ~~The method according to claim 26~~, wherein the hydrolysate is the drug compound.

Claim 28 (Previously Presented): The method according to claim 26, wherein the hydrolysate is a compound comprising the residue of drug compound bound with a part of the spacer.

Claim 29 (Currently Amended): A method for measurement of content of a residue of a drug compound introduced to a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate, the hydrolysate is a compound comprising the residue of drug compound bound with a part of the spacer, and ~~The method according to claim 28, wherein~~ the part of the spacer is one amino acid derived from the spacer.

Claim 30 (Currently Amended) The method according to claim ~~26~~ 27, wherein the polymer carrier is a polysaccharide derivative having carboxyl groups.

Claim 31 (Currently Amended): The method according to claim ~~30~~ 26, wherein the polymer carrier is a carboxy(C_{1-4})alkyldextran polyalcohol.

Claim 32 (Previously Presented): The method according to claim 26, wherein the drug compound introduced to the drug delivery system compound is an antineoplastic agent or an anti-inflammatory agent.

Claim 33 (Previously Presented): The method according to claim 26, wherein the spacer is a tetrapeptide represented by -Gly-Gly-Phe-Gly- (SEQ ID NO. 1) from the N-terminal or a tetrapeptide represented by -Gly-Gly-Gly-Phe- (SEQ ID NO. 8) from the N-terminal.

Claim 34 (Previously Presented): A method for measuring a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate, and

wherein the spacer is a group represented by -Gly-Gly-Phe-Gly-HN-Y'-CH_2-O-CO- (SEQ ID NO. 1) from the N-terminal or a group represented by -Gly-Gly-Gly-Phe-NH-Y'-CH_2-O-CO- (SEQ ID NO. 8) from the N-terminal wherein Y' represents p-phenylene group.

Claim 35 (Previously Presented): A method for measuring a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase comprising α-chymotrypsin or papain, and measuring the resulting hydrolysate.

Claim 36 (Currently Amended): A method for measurement of content of a residue of a drug compound introduced to a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate, and ~~The method according to claim 26, wherein~~ the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

Claim 37 (Previously Presented): (Twice Amended) The method according to claim 34, which is used for measurement of a drug delivery system compound in which a carboxy(C_{1-4})alkyldextran polyalcohol and (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano3'4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione are bound to each other by a spacer comprising a tetrapeptide represented by -Gly-Gly-Phe-Gly- (SEQ ID NO. 1) or a tetrapeptide represented by -Gly-Gly-Gly-Phe- (SEQ ID NO. 8) from the N-terminal.

Claim 38 (Previously Presented): A method for measuring a drug delivery system compound in which a polymer carrier comprising carboxy(C_{1-4})alkyldextran polyalcohol and a drug compound comprising (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano3'4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione are bound to each other by a spacer comprising a tetrapeptide represented by -Gly-Gly-Phe-Gly- (SEQ ID NO. 1) or a tetrapeptide represented by -Gly-Gly-Gly-Phe- (SEQ ID NO. 8) from the N-terminal, which comprises treating the drug delivery system compound with a peptidase comprising α-chymotrypsin or papain, and measuring (1S,9S)-9-ethyl-5-fluoro-1-glycylamino-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione as the resulting hydrolysate.